Differences in the intracellular fate of free and polymer-bound doxorubicin
- 1 April 2002
- journal article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 80 (1-3), 101-117
- https://doi.org/10.1016/s0168-3659(02)00016-0
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugsJournal of Controlled Release, 2002
- A Possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrierEuropean Journal Of Cancer, 1999
- HPMA copolymer–anticancer drug–OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitroInternational Journal of Cancer, 1998
- Dose-dependent Increase in Sensitivity to Calcium-induced Mitochondrial Dysfunction and Cardiomyocyte Cell Injury by DoxorubicinJournal of Molecular and Cellular Cardiology, 1996
- Drug-polymer conjugatesAnti-Cancer Drugs, 1992
- Targetable Polymeric Anticancer DrugsAnnals of the New York Academy of Sciences, 1991
- Antibody-directed affinity therapy applied to the immune system: In vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibodyClinical Immunology and Immunopathology, 1988
- Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to ratsBiochimica et Biophysica Acta (BBA) - General Subjects, 1986
- Interaction of a Cationic N-(2-hydroxypropyl)methacrylamide Copolymer with Rat Visceral Yolk Sacs Cultured in vitro and Rat Liver in vivoJournal of Bioactive and Compatible Polymers, 1986
- Biological properties of targetable poly[N-(2-hydroxypropyl)-methacrylamide]-antibody conjugatesJournal of Controlled Release, 1985